Immune-based treatments for aggressive Group 3 medulloblastoma

Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology

NIH-funded research St. Jude Children's Research Hospital · NIH-11162311

Working to unlock the immune system to create new treatments for children with high-risk Group 3 medulloblastoma.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionSt. Jude Children's Research Hospital NIH-funded
Lab location1 site (Memphis, United States)
Project IDNIH-11162311 on NIH RePORTER

What this research studies

This project maps the immune cells and their neighborhoods inside aggressive Group 3 medulloblastoma to learn how the tumor hides from the immune system. Researchers will use single-cell and spatial multi-omics to profile individual cells and tumor environments and perform CRISPR-based screens in immunocompetent mouse models that mimic the human tumor. The team aims to find immune-suppressing interactions and specific targets that could be turned into immune therapies for children. The overall goal is to generate treatment leads that can move toward clinical testing for high-risk pediatric patients.

Who could benefit from this research

Good fit: Children with high-risk Group 3 medulloblastoma, especially tumors with MYC overexpression or those with recurrent or treatment-refractory disease, would be the primary candidates for eventual therapies from this work.

Not a fit: Children with other medulloblastoma subgroups or unrelated cancers are unlikely to receive direct benefit from this specific project.

Why it matters

Potential benefit: Could lead to new immune-based therapies that improve survival and reduce harmful long-term effects for children with high-risk Group 3 medulloblastoma.

How similar studies have performed: Single-cell and spatial immune profiling have revealed actionable targets in other cancers, but applying an integrated systems immunology and CRISPR screening approach to Group 3 medulloblastoma is largely novel.

Where this research is happening

Memphis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.